Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456903 | 0.79 | TSHR (0.42) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL848744 | 0.77 | CA12 (0.40) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL19195262 | 0.73 | — | — | |
| SCHEMBL7104114 | 0.72 | CA12 (0.40) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL29616127 | 0.71 | KMT2A (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL18512540 | 0.71 | CA12 (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL18512541 | 0.71 | CA12 (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL282713 | 0.70 | CA12 (0.50) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL3229087 | 0.70 | CA12 (0.38) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL20211819 | 0.70 | CA12 (0.42) | TSHRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | TSHR 3188/4885CA12 3586/4885CA1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.